Navigation Links
Innophos Holdings, Inc. Schedules Call to Discuss Fourth Quarter And Full Year 2012 Results

CRANBURY, N.J., Feb. 6, 2013 /PRNewswire/ -- Innophos Holdings, Inc. (NASDAQ: IPHS), a leading international producer of performance-critical and nutritional specialty ingredients, today announced that it will host a live conference call on Friday, February 15, 2013 at 10:00 am ET to discuss its fourth quarter and full year 2012 results.

The press release detailing fourth quarter and full year results will be issued on Thursday, February 14, 2013 after market close.

The conference call can be accessed by dialing 888-206-4065(U.S.) or 630-827-5974 (international) and entering passcode 34232459.  A replay will be available between 1:00 pm ET on February 15 and 1:00 pm ET on February 28, 2013.  The replay is accessible by dialing 888-843-7419 (U.S.) or 630-652-3042 (international) and entering passcode 6861213#.

If you would like to pre-register for the conference call use the following link: is highly recommended, as it will provide you immediate entry into the call and will facilitate the timely start of the conference. You will receive a code that allows you to enter the call directly.  Pre-registration only takes a few moments, and you may do so at any time, including up to and after call start time. To pre-register, please click the link above. Alternately, if you would rather be placed into the call by an operator, please call at least 15 minutes prior to call start time.

Alternately, the webcast of the conference call can be accessed live and as a replay at Innophos' web site in the Investor Relations Events section.

About Innophos Holdings, Inc.
Innophos is a leading international producer of performance-critical and nutritional specialty ingredients, with applications in food, beverage, dietary supplements, pharmaceutical, oral care and industrial end markets.  Innophos combines more than a century of experience in specialty phosphate manufacturing with a growing capability in a broad range of other specialty ingredients to supply a product range produced to stringent regulatory manufacturing standards and the quality demanded by customers worldwide.  Innophos is continually developing new and innovative specialty ingredients addressing specific customer applications and supports these high-value products with industry-leading technical service.  Headquartered in Cranbury, New Jersey, Innophos has manufacturing operations in Nashville, TN; Chicago Heights, IL; Chicago (Waterway), IL; Geismar, LA; Ogden, UT; North Salt Lake, UT; Paterson, NJ; Green Pond, SC; Port Maitland, ON (Canada); and Coatzacoalcos, Veracruz and San Jose de Iturbide (Mission Hills), Guanajuato (Mexico). For more information please visit 'IPHS-G'

Innophos Investor Relations 

FTI Consulting, Inc.(609) 366-1299


Matt Steinberg(212) 850-5600

SOURCE Innophos Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Innophos To Present At 2012 KeyBanc Capital Markets Basic Materials & Packaging Conference
2. Organovo Holdings, Inc. announces redemption of 2.9 million outstanding warrants
3. Free Research Report on Laboratory Corp. of America Holdings, Sony Corp., Cyberonics, Inc., Olin Corp. and Deluxe Corp.
4. Market Boosted by Strong Tech Earnings: Bank of America Corp., MAP Pharmaceuticals Inc., Swingplane Ventures Inc., World Moto, Inc., Organovo Holdings, Inc.
5. Zacks Sell List Highlights: J.C. Penney, Spirit AeroSystems Holdings, The New York Times and Jazz Pharmaceuticals
6. China Pharma Holdings, Inc. Reports Third Quarter 2012 Financial Results
7. Zimmer Holdings, Inc. Reports Third Quarter 2012 Financial Results
8. China Pharma Holdings, Inc. Reports Second Quarter 2012 Financial Results
9. RxAlly Member Pharmacies Invited To Become The Preferred Network For Smart Insurance Company Holdings, Inc.
10. InfuSystem Holdings, Inc. Reports $14.1 Million of Revenues for the Second Quarter of 2012; Announces Annualized Cost Savings in Excess of $1 million
11. China Pharma Holdings, Inc. to Report Second Quarter of Fiscal Year 2012 Financial Results on August 15, 2012
Post Your Comments:
(Date:11/26/2015)... , Países Bajos, November 26, 2015 ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... la inmunoterapia con la terapia fotodinámica de Bremachlorin para ... Un nuevo enfoque combina la inmunoterapia con la terapia ... Clinical Cancer Research . --> ...
(Date:11/26/2015)... UTRECHT , Nederland, November 26, 2015 ... --> Een nieuwe aanpak combineert ... van gevorderde kanker. ... -->      (Photo: ... van het Leids Universitair Medisch Centrum (LUMC) ...
(Date:11/26/2015)... November 26, 2015 3D bioprinting market ... according to a new report by Grand View Research Inc. ... (CKD) which demands kidney transplantation is expected to boost the ... substitute for organ transplantation. --> 3D bioprinting market ... according to a new report by Grand View Research Inc. ...
Breaking Medicine Technology:
(Date:11/26/2015)... , ... November 26, 2015 , ... ... abuse located in central Michigan, have come together on Thanksgiving Day to share ... video, available for viewing on the Serenity Point YouTube channel, patients displayed what ...
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think Thanksgiving, they ... to buy during the Black Friday and Cyber Monday massage chair sales ... the Internet high and low to find the best massage chair deals, they can ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... eReferral system for diagnostic imaging in the Waterloo region. Using the Ocean Platform, ... Medicine tests directly from their electronic medical record (EMR) without the need for ...
(Date:11/26/2015)... Ashburn, VA (PRWEB) , ... November 26, 2015 ... ... Planners, an American Express Travel Representative. As a franchise owner, Somu now offers ... range of cruise, destination wedding packages, private cruise sales, as well as, cabin ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent ... and the need to integrate dose form selection in early phase drug development. ... membership organization supporting and bringing together the UK’s emerging life sciences companies, corporate ...
Breaking Medicine News(10 mins):